Events

New antibody-drug conjugate shows early promise against all forms of melanoma

The investigational drug DEDN6526A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against different forms of melanoma—cutaneous, mucosal, and ocular—according to results of a first-in-human phase I clinical trial presented here at the AACR Annual Meeting 2014, April 5-9.

Read More
MRV News
Melanoma News
Archive
Menu